Zahra Karimizadeh

Dr. Zahra Karimizadeh


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MHMohammad Amin Habibi
Mohammad Amin Habibi
AZAli Zand
Ali Zand
BRBehrouz Robat-Jazi
Behrouz Robat-Jazi
AKAlireza Khodadadiyan
Alireza Khodadadiyan
MDMohsen Dashti
Mohsen Dashti
SASajjad Ahmadpour
Sajjad Ahmadpour
Neuroblastoma (NB) is a common and life-threatening pediatric solid tumor with a poor prognosis, especially in high-risk patients. Although anti-disialogan

10 September 2025 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
MHMohammad Amin Habibi
Mohammad Amin Habibi
NNNegar Nejati
Negar Nejati
MNMajed Bahri Najafi
Majed Bahri Najafi
AKAlireza Khodadadiyan
Alireza Khodadadiyan
MDMohsen Dashti
Mohsen Dashti
STSoheil Tavakolpour
Soheil Tavakolpour
This review focuses on enhancing T-cell infiltration in glioblastoma (GBM) while overcoming its immunosuppressive tumor microenvironment (TME). Key strategies include targeting myeloid-derived suppressor cells (MDSCs) to reduce immunosuppression and repolarizing tumor-associated macrophages (TAMs) from an M2 (immunosuppressive) phenotype to an M1 (proinflammatory) phenotype to increase T-cell function. Administering chemokines can help attract more effector T cells to the tumor site. Combining immune checkpoint inhibitors (ICIs) with other treatments can further increase T cell activity. To make immunotherapy more effective in GBM, it is also essential to address the immunosuppressive signals in the TME, such as transforming growth factor beta (TGF-β) and interleukin-10 (IL-10).

Verified
Journal Article
Open access
PDF file
AKAtieh Karimzadeh
Atieh Karimzadeh
ZKZahra Karimizadeh
Zahra Karimizadeh
NHNazila Heidari
Nazila Heidari
SPSamira Parviziomran
Samira Parviziomran
SRSepehr Ramezanipour
Sepehr Ramezanipour
AMAbbas Mi
Abbas Mi
Background: Assisted reproductive technology (ART) is increasingly utilized worldwide, and approximately 30% of ART pregnancies result in twin gestations. Chorionicity strongly influences perinatal risk, yet its specific impact on ART-conceived twins has not been systematically clarified. Objective: To compare obstetrical and neonatal outcomes in assisted ART-conceived monochorionic (MC) versus dichorionic (DC) twin pregnancies and evaluate the impact of chorionicity on maternal and perinatal outcomes. Methods: This systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42024600292). PubMed, Scopus, and Web of Science were searched through October 2024 for studies comparing obstetrical and neonatal outcomes in ART-conceived monochorionic and dichorionic twin pregnancies. Eligible studies were qualitatively synthesized. Results: Thirty-five studies comprising 15,648 ART-conceived twin pregnancies were included, including 371 monochorionic and 15,277 dichorionic pregnancies. MC pregnancies consistently demonstrated less favorable perinatal outcomes compared with DC pregnancies, including an earlier gestational age at delivery, increased prematurity, lower birth weight, and higher rates of perinatal mortality. By contrast, maternal complications, such as hypertensive disorders, gestational diabetes mellitus, PROM, and cesarean delivery, varied considerably across the studies without a consistent association with chorionicity. The baseline maternal characteristics were generally comparable between the groups. Conclusions: Monochorionicity in ART-conceived twin pregnancies is associated with increased adverse neonatal and perinatal outcomes, particularly prematurity and perinatal mortality, while maternal outcomes appear less clearly influenced by chorionicity. Standardized prospective studies are needed to further clarify the chorionicity-specific risks in ART twin pregnancies.